Relevant bibliographies by topics / Hepatocellular Carcinoma HSC

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Hepatocellular Carcinoma HSC'

Author: Grafiati
Published: 9 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatocellular Carcinoma HSC.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hepatocellular Carcinoma HSC"

1

Wang, Pei-Wen, Tung-Yi Lin, Pei-Ming Yang, Chau-Ting Yeh, and Tai-Long Pan. "Hepatic Stellate Cell Modulates the Immune Microenvironment in the Progression of Hepatocellular Carcinoma." International Journal of Molecular Sciences 23, no. 18 (2022): 10777. http://dx.doi.org/10.3390/ijms231810777.

Full text
Abstract:
Hepatocellular carcinoma (HCC) is a major cause of increases in the mortality rate due to cancer that usually develops in patients with liver fibrosis and impaired hepatic immunity. Hepatic stellate cells (HSCs) may directly or indirectly crosstalk with various hepatic cells and subsequently modulate extracellular remodeling, cell invasion, macrophage conversion, and cancer deterioration. In this regard, the tumor microenvironment created by activated HSC plays a critical role in mediating pathogenesis and immune escape during HCC progression. Herein, intermediately differentiated human liver
APA, Harvard, Vancouver, ISO, and other styles
2

Mailloux, Adam, and Pearlie Epling-Burnette. "Collagen matrix deposition by hepatic stellate cells protects hepatocellular carcinoma from NK-mediated cytotoxicity (P2013)." Journal of Immunology 190, no. 1_Supplement (2013): 53.7. http://dx.doi.org/10.4049/jimmunol.190.supp.53.7.

Full text
Abstract:
Abstract Liver fibrosis (LF), a leading risk factor for hepatocellular carcinoma (HCC), is caused by collagen-producing hepatic stellate cells (HSC) activated during chronic inflammation secondary to hepatitis-C infection, or alcohol liver disease (ALD). NK cells promote disease resolution via RAE1-dependant HSC clearance. A defect in NK function by an ill-defined mechanism contributes to a pro-fibrotic response. Using an engineered bioartifical collagen matrix, the expression of inhibitory leukocyte associated IgG-like receptor-1 (LAIR-1) was increased on dividing NK cells and IL-2-induced NK
APA, Harvard, Vancouver, ISO, and other styles
3

Jia, Shu-Qin, Jian-Jun Ren, Pei-De Dong, and Xing-Kai Meng. "Probing the Hepatic Progenitor Cell in Human Hepatocellular Carcinoma." Gastroenterology Research and Practice 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/145253.

Full text
Abstract:
Objective. The intrahepatic stem cells, also known as hepatic progenitor cells (HPCs), are able to differentiate into hepatocytes and bile duct epithelia. By exposure of different injuries and different hepatocarcinogenic regimens, the mature hepatocytes can no longer effectively regenerate; stem cells are involved in the pathogenesis of hepatocellular carcinoma.Methods. Immunohistochemistry was performed on 107 paraffin-embedded hepatocellular carcinoma specimens with the marker of hepatocyte and hepatocellular carcinoma (HepPar1), biliary differentiation (CK7,CK19), haemopoietic stem cell (H
APA, Harvard, Vancouver, ISO, and other styles
4

Xiong, Hao, and Jinsheng Guo. "Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation." Pharmaceuticals 18, no. 4 (2025): 507. https://doi.org/10.3390/ph18040507.

Full text
Abstract:
Hepatic stellate cells (HSC) are the major source of myofibroblasts (MFB) in fibrosis and cancer- associated fibroblasts (CAF) in both primary and metastatic liver cancer. Over the past few decades, there has been significant progress in understanding the cellular and molecular mechanisms by which liver fibrosis and HCC occur, as well as the key roles of HSC in their pathogenesis. HSC-targeted approaches using specific surface markers and receptors may enable the selective delivery of drugs, oligonucleotides, and therapeutic peptides that exert optimized anti-fibrotic and anti-HCC effects. Rec
APA, Harvard, Vancouver, ISO, and other styles
5

Wu, Mengna, Huajie Miao, Rong Fu, Jie Zhang, and Wenjie Zheng. "Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma." Current Molecular Pharmacology 13, no. 4 (2020): 261–72. http://dx.doi.org/10.2174/1874467213666200224102820.

Full text
Abstract:
: Liver cancer is a leading cause of cancer-related death worldwide, in which hepatocellular carcinoma (HCC) accounts for the majority. Despite the progression in treatment, the prognosis remains extremely poor for HCC patients. The mechanisms of hepatocarcinogenesis are complex, of which fibrosis is acknowledged as the pre-cancerous stage of HCC. Approximately, 80-90% of HCC develops in the fibrotic or cirrhotic livers. Hepatic stellate cells (HSCs), the main effector cells of liver fibrosis, could secret various biological contents to maintain the liver inflammation. By decades, HSCs are inc
APA, Harvard, Vancouver, ISO, and other styles
6

Quiroz Reyes, Adriana G., Sonia A. Lozano Sepulveda, Natalia Martinez-Acuña, et al. "Cancer Stem Cell and Hepatic Stellate Cells in Hepatocellular Carcinoma." Technology in Cancer Research & Treatment 22 (January 2023): 153303382311636. http://dx.doi.org/10.1177/15330338231163677.

Full text
Abstract:
Hepatocellular carcinoma (HCC) is the most common liver cancer. It is highly lethal and has high recurrence. Death among HCC patients occur mainly due to tumor progression, recurrence, metastasis, and chemoresistance. Cancer stem cells (CSCs) are cell subpopulations within the tumor that promote invasion, recurrence, metastasis, and drug resistance. Hepatic stellate cells (HSCs) are important components of the tumor microenvironment (TME) responsible for primary secretory ECM proteins during liver injury and inflammation. These cells promote fibrogenesis, infiltrate the tumor stroma, and contr
APA, Harvard, Vancouver, ISO, and other styles
7

Liu, Man, Jingying Zhou, Xiaoyu Liu, et al. "Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma." Gut 69, no. 2 (2019): 365–79. http://dx.doi.org/10.1136/gutjnl-2018-317257.

Full text
Abstract:
ObjectiveHepatocellular carcinoma (HCC), mostly developed in fibrotic/cirrhotic liver, exhibits relatively low responsiveness to immune checkpoint blockade (ICB) therapy. As myeloid-derived suppressor cell (MDSC) is pivotal for immunosuppression, we investigated its role and regulation in the fibrotic microenvironment with an aim of developing mechanism-based combination immunotherapy.DesignFunctional significance of MDSCs was evaluated by flow cytometry using two orthotopic HCC models in fibrotic liver setting via carbon tetrachloride or high-fat high-carbohydrate diet and verified by clinica
APA, Harvard, Vancouver, ISO, and other styles
8

Subramanian, Pallavi, Jochen Hampe, Frank Tacke, and Triantafyllos Chavakis. "Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)." International Journal of Molecular Sciences 23, no. 13 (2022): 6996. http://dx.doi.org/10.3390/ijms23136996.

Full text
Abstract:
The prevalence of nonalcoholic fatty liver disease (NAFLD), recently also re-defined as metabolic dysfunction associated fatty liver disease (MAFLD), is rapidly increasing, affecting ~25% of the world population. MALFD/NAFLD represents a spectrum of liver pathologies including the more benign hepatic steatosis and the more advanced non-alcoholic steatohepatitis (NASH). NASH is associated with enhanced risk for liver fibrosis and progression to cirrhosis and hepatocellular carcinoma. Hepatic stellate cells (HSC) activation underlies NASH-related fibrosis. Here, we discuss the profibrogenic path
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Wen-Hung, Kuo-Yu Hsuan, Ling-Ya Chu, et al. "Anticancer Effects of Salvia miltiorrhiza Alcohol Extract on Oral Squamous Carcinoma Cells." Evidence-Based Complementary and Alternative Medicine 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/5364010.

Full text
Abstract:
Researchers have reported significant effects from Danshen (Salvia miltiorrhiza) in terms of inhibiting tumor cell proliferation and promoting apoptosis in breast cancer, hepatocellular carcinomas, promyelocytic leukemia, and clear cell ovary carcinomas. Here we report our data indicating that Danshen extracts, especially alcohol extract, significantly inhibited the proliferation of the human oral squamous carcinoma (OSCC) cell lines HSC-3 and OC-2. We also observed that Danshen alcohol extract activated the caspase-3 apoptosis executor by impeding members of the inhibitor of apoptosis (IAP) f
APA, Harvard, Vancouver, ISO, and other styles
10

MAN, LIU, Jingying Zhou, John Wong, Anthony W. H. Chan, Zhiwei Chen, and Alfred S. L. Cheng. "Delineating the epigenetic regulation of myeloid derived suppressor cell generation in hepatocellular carcinoma associated with cirrhosis." Journal of Immunology 198, no. 1_Supplement (2017): 205.14. http://dx.doi.org/10.4049/jimmunol.198.supp.205.14.

Full text
Abstract:
Abstract Hepatocellular carcinoma (HCC) is the most common liver tumor with dismal prognosis. Since most liver tumors arise in a context of chronic inflammation associated with fibrosis, tumor microenvironment plays a critical role in liver carcinogenesis. Myeloid derived suppressor cell (MDSC) is a population of immature myeloid cells that undermine immune surveillance and facilitate tumor immune escape. As a key driver of liver fibrosis, activated hepatic stellate cell (HSC) has been recently shown to induce MDSC generation through cell-cell contact and/or secreted soluble factors. Given the
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hepatocellular Carcinoma HSC"

1

龔衍峰 and Hin-fung Tony Kung. "The impact of heat on hepatocellular carcinoma (HCC)." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B4073867X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kung, Hin-fung Tony. "The impact of heat on hepatocellular carcinoma (HCC)." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B4073867X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Guang. "Role of Notch Signaling in Hepatocellular Carcinoma (HCC)." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/18718.

Full text
Abstract:
Liver cancer is the 6th most common cancer worldwide and Australia’s fastest growing malignancy both in incidence and mortality. Although great improvement in early diagnosis and treatment approach have been achieved during last two decades, patients with HCC still have a dismal prognosis with a mortality-to-incidence ratio close to 1, meaning that the disease is almost uniformly fatal. One of explanations for such a dismal prognosis for HCC is the existence of heterogeneity in HCC, in which HCC is composed of liver cancer stem cells and mature HCC cells. Previous data suggested that liver can
APA, Harvard, Vancouver, ISO, and other styles
4

Mckiver, Bryan D. "SND1-Targeted Gene Therapy for Hepatocellular Carcinoma." VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5676.

Full text
Abstract:
Staphylococcal nuclease and tudor-domain containing 1 (SND1) is an oncogene for a wide variety of cancers, including hepatocellular carcinoma (HCC). SND1 is a multifunctional protein regulating gene expression of proto-oncogenes and tumor suppressor genes, making SND1 a prime target for developing cancer therapeutics. This notion is especially attributed to HCC as most patients are diagnosed in advanced stages and the therapeutic options available for these patients are severely limited. In this study, we evaluated the therapeutic potential of a replication-defective adenovirus vector deliveri
APA, Harvard, Vancouver, ISO, and other styles
5

Pascut, Devis. "Molecular insights for overcoming Hepatocellular Carcinoma." Doctoral thesis, Università degli studi di Trieste, 2012. http://hdl.handle.net/10077/7859.

Full text
Abstract:
2010/2011<br>SUMMARY Introduction. Hepatocellular Carcinoma (HCC) ranks fifth in frequency of cancers in the world. Orthotopic Liver Transplantation (OLT) or liver resection represents the best treatments for HCC. However, most patients cannot be subjected to potential curative OLT or resection because of extensive tumor involvement of the liver, metastasis, invasion of the portal vein or advanced underlying hepatocellular disease at the time of diagnosis. Systemic chemotherapy or chemoembolization represent a good alternative for the treatment, however drug therapy of cancer in general i
APA, Harvard, Vancouver, ISO, and other styles
6

Chan, Chun-Fai. "Study of cancer vaccine candidates for human hepatocellular carcinoma (HCC) /." View abstract or full-text, 2004. http://library.ust.hk/cgi/db/thesis.pl?BIOL%202004%20CHAN.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tam, Hoy-kam Aegean, and 譚凱琴. "Epigenetic dysregulation of microRNA-9 (miRNA-9) in hepatocellular carcinoma (HCC)." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46455425.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Khan, Maheen. "AEG-1 KNOCKOUT SENSITIZES HEPATOCELLULAR CARCINOMA (HCC) CELLS TO IONIZING RADIATION." VCU Scholars Compass, 2019. https://scholarscompass.vcu.edu/etd/5853.

Full text
Abstract:
Liver cancer is the fourth leading cause of cancer-associated deaths globally, and among primary liver cancers, hepatocellular carcinoma (HCC) encompasses 75-85% of all cases. HCC is a highly lethal disease due to limited treatment options – only a small subset of patients qualify for surgical resection or transplantation; the remaining patients often display resistance to radiation therapy or chemotherapy. Overexpression of the oncogene astrocyte elevated gene-1 (AEG-1) is associated with poorer survival and increased tumor recurrence in HCC, and numerous studies show its role in initiation o
APA, Harvard, Vancouver, ISO, and other styles
9

Kienlein, Andreas. "Lebertransplantation bei Patienten mit hepatozellulärem Karzinom. Eine retrospektive Studie am Universitätsklinikum Leipzig im Zeitraum von 1994 bis 2010. Charakterisierung des Patientenkollektivs und Analyse von Einflussfaktoren auf Überleben und Outcome." Doctoral thesis, Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-205991.

Full text
Abstract:
Für Lebertransplantationen bei Patienten mit hepatozellulärem Karzinom stellt sich angesichts der defizitären Organspendesituation die berechtigte Frage, unter welchen Bedingungen diese Form der Therapie ein gutes Outcome für die Patienten verspricht und somit keine Verschwendung der ohnehin knappen Ressourcen darstellt. Ziel dieser Arbeit war es, ein Kollektiv aus 98 Patienten, die an einem hepatozellulären Karzinom erkrankten und im Zeitraum von 1994 bis einschließlich 2010 am Universitätsklinikum Leipzig eine Lebertransplantation erhielten, retrospektiv zu charakterisieren und den Einflus
APA, Harvard, Vancouver, ISO, and other styles
10

Chicherova, Ievgeniia. "Netrin-1 and neurons in hepatocellular carcinoma." Electronic Thesis or Diss., Lyon, 2022. https://n2t.net/ark:/47881/m60r9pbg.

Full text
Abstract:
L'inflammation hépatique chronique peut entraîner des maladies chroniques du foie (MCF), notamment l'hépatite, la cirrhose et le carcinome hépatocellulaire (CHC), qui est la tumeur maligne primaire du foie la plus fréquente et le troisième cancer le plus fréquent en termes de mortalité dans le monde. Indépendamment des facteurs étiologiques, toutes les MCFs partagent de nombreux mécanismes physiopathologiques communs : réponse aux protéines non pliées (UPR), inflammation chronique et fibrose. A l'aide d'un modèle animal et d'échantillons cliniques nous avons étudié un autre dénominateur commun
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hepatocellular Carcinoma HSC"

1

Bamia, Christina, Sherri Stuver, and Lorelei Mucci. Cancer of the Liver and Biliary Tract. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190676827.003.0012.

Full text
Abstract:
Primary liver cancer is one of the most commonly occurring cancers globally, and is the second most common cause of cancer death worldwide. There are two major histologic forms of primary liver cancer: hepatocellular carcinoma (HCC) and cholangiocarcinoma. It is a rapidly and almost uniformly fatal disease, yet there is already sufficient knowledge about its major risk factors, many of which are modifiable, to make primary prevention effective. Primary liver cancer is one of the first common human cancer that was found to have an infectious etiology, with hepatitis B virus (HBV) and hepatitis
APA, Harvard, Vancouver, ISO, and other styles
2

Thomas London, W., Jessica L. Petrick, and Katherine A. McGlynn. Liver Cancer. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0033.

Full text
Abstract:
Primary liver cancer is the sixth most frequently occurring cancer in the world and the second most common in terms of cancer deaths. The global burden of liver cancer is borne principally by countries in East Asia and Africa, where 80% of liver cancer arises. Incidence rates of liver cancer, however, have begun to decline in Asia, while rates are increasing in low-rate areas such as Europe and North America. The dominant histology of liver cancer in almost all countries is hepatocellular carcinoma (HCC). The major risk factors for HCC—chronic infection with either hepatitis B virus (HBV) or h
APA, Harvard, Vancouver, ISO, and other styles
3

Keshav, Satish, and Palak Trivedi. Liver cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0218.

Full text
Abstract:
Primary hepatocellular carcinoma (HCC) arises from hepatocytes and is one of the commonest solid-organ malignancies in the world, particularly in the Far East and in sub-Saharan Africa. Cholangiocarcinoma arises from the biliary epithelium. The incidence is rising in the West, and primary sclerosing cholangitis (PSC) is an important risk factor (15% lifetime risk). Other forms of liver cancer include metastatic cancer, which is much more common in the West than any primary liver cancer, accounting for 90% of liver cancers and for which common primary sites are the colon, the stomach, the breas
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hepatocellular Carcinoma HSC"

1

Aravalli, Rajagopal N., and Clifford J. Steer. "Pathophysiology of HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-09414-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carr, Brian I., and Srikanth Nagalla. "Medical Therapy of HCC." In Hepatocellular Carcinoma. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-376-3_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aravalli, Rajagopal N., and Clifford J. Steer. "Molecular Mechanisms of HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-09414-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Carr, Brian I. "HCC and Its Microenvironment." In Hepatocellular Carcinoma. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34214-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Robertson, Chadia L., Devanand Sarkar, and Arun J. Sanyal. "Obesity, NASH, and HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34214-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Agnello, Francesco, and Giuseppe Brancatelli. "Computed Tomography of HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34214-6_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Carr, Brian I., Srikanth Nagalla, and Ravit Geva. "Medical Therapy of HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34214-6_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Loosen, Sven H., Christoph Roderburg, and Tom Luedde. "Gut Microbiota and HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34214-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Carr, Brian I., and Susan Kralian. "Molecular Targeted Therapies for HCC." In Hepatocellular Carcinoma. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-376-3_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Aravalli, Rajagopal N., and Clifford J. Steer. "Novel Therapeutic Strategies to Combat HCC." In Hepatocellular Carcinoma. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-09414-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hepatocellular Carcinoma HSC"

1

Glushchenko, A. G., M. D. Chanyshev, N. V. Vlasenko, V. V. Makashova, and K. F. Khafizov. "THE SEARCH FOR HBV MUTATIONS POTENTIALLY ASSOCIATED WITH A HIGH RISK OF LIVER CIRRHOSIS AND HCC IN VIRAL HEPATITIS B." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-179.

Full text
Abstract:
In this work, a collection of whole-genome sequences of Hepatitis B virus was obtained and analyzed. As a result, a number of mutations have been associated with a high risk of liver cirrhosis and hepatocellular carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
2

Mohsin, Abeer. "Effects of Induced Oxidative Stress as a Therapeutic Approach Against Hepatocellular Carcinoma." In INTERNATIONAL CONFERENCE ON BIOLOGICAL RESEARCH AND APPLIED SCIENCE. Jinnah University for Women, Karachi,Pakistan, 2022. http://dx.doi.org/10.37962/ibras/2022/14-16.

Full text
Abstract:
Hepatocellular carcinoma is a type of primary liver cancer that accounts for 75% of all liver cancers globally. HCC is said to be the 6th most prevalent cancer and the 3rd major cause of cancer related death accounting for approximately 0.32 million annual deaths across the globe. The increasing incidence of HCC with a very high mortality rate is a major problem encountered by many regions of the world including both developing and developed countries and is a source of increasing economic burden. Therefore, effective treatment strategies for HCC are the need of the hour. Oxidative stress can
APA, Harvard, Vancouver, ISO, and other styles
3

Lei, Ningjing, Bo Peng, Yang Li, Yurong Chai, and Jianying Zhang. "Abstract 5381: p62/IMP2 promotes hepatocellular carcinoma (HCC) progression." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5381.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Babu, Vothani Sarath, Chittoor Pallavi, Gurvinder Singh, Rajesh Kumar, and Arun Sharma. "Polymeric nanoparticles based treatment approaches for hepatocellular carcinoma (HCC)." In THE FOURTH SCIENTIFIC CONFERENCE FOR ELECTRICAL ENGINEERING TECHNIQUES RESEARCH (EETR2022). AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0168936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Srivastava, Jyoti, Devaraja Rajasekaran, Ayesha Siddiq, et al. "Abstract 5400: A novel combinatorial therapy for hepatocellular carcinoma (HCC)." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5400.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rajesh, Sanapala, Nurul Amin Choudhury, and Soumen Moulik. "Hepatocellular Carcinoma (HCC) Liver Cancer prediction using Machine Learning Algorithms." In 2020 IEEE 17th India Council International Conference (INDICON). IEEE, 2020. http://dx.doi.org/10.1109/indicon49873.2020.9342443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bisceglie, Adrian M. Di. "Abstract IA37: Prevention of Hepatocellular Carcinoma (HCC) with antiviral therapy." In Abstracts: AACR International Conference: New Frontiers in Cancer Research; January 18-22, 2017; Cape Town, South Africa. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.newfront17-ia37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lefrère, J. J., D. Gozin, J. P. Soulier, P. Mavier, L. Bettan, and D. Dhumeaux. "SPECIFICITY OF INCREASED DES-GAMMA-CARBOXYPROTHROMBIN AS A MARKER OF HEPATOCELLULAR CARCINOMA AFTER VITAMIN K INJECTION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644319.

Full text
Abstract:
An elevation of des-gamma-carboxyprothrombin (DCP) has been observed in about 70 % of cases of hepatocellular carcinoma (HCC). Howewer, an increased DCP is not specific of HCC. Oral anticoagulant therapy increases the DCP level by preventing the gamma-carboxylation of prothrombin : thereafter an increased DCP can not be used as an HCC marker before three weeks have elapsed after stopping anti vitamin K therapy. Furthermore, since vitamin K is necessary for the gamma-carboxylation of vitamin K dependent factors, a vitamin K deficiency increases the DCP level long before the modification of the
APA, Harvard, Vancouver, ISO, and other styles
9

Michalski, M., E. Aschenbrenner, K. Pollinger, M. Müller-Schilling, and K. Gülow. "Induction of cell death in hepatocellular carcinoma (HCC) via energy depletion." In 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0038-1677219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Michalski, M., O. Wiesner, M. Müller-Schilling, and K. Gülow. "Dimethyl fumarate (DMF) inhibits migration and proliferation of hepatocellular carcinoma (HCC)." In 36. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402232.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hepatocellular Carcinoma HSC"

1

Zheng, Jiaxi, and Haihua Yang. Clinical Benefits of Immune Checkpoint Inhibitors and Predictive Value of Tumor Mutation Burden in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.1.0008.

Full text
Abstract:
Review question / Objective: Is immunotherapy associated with beneficial clinical outcomes for hepatocellular carcinoma (HCC) and how can combination immunotherapy be deployed to produce the best benefit? Is tumor mutation burden (TMB) a predictive biomarker for immune‐checkpoint inhibitors? Condition being studied: To this date, about 50 single-arm clinical trials and several randomized control trials (RCTs) presented final or interim results of investigations on the efficacy of PD-1/PD-L1 inhibitors for advanced HCC. In the CheckMate 459, IMbrave 050, and ORIENT-32, immunotherapies were foun
APA, Harvard, Vancouver, ISO, and other styles
2

Jin, Hongyu, and Man Zhang. LR-5 by LI-RADS under contrast enhanced ultrasonography manifests satisfactory diagnostic performance for hepatocellular carcinoma: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0011.

Full text
Abstract:
Review question / Objective: To evaluate the relative diagnostic sensitivity, specificity, and accuracy of LR-5 under contrast-enhanced ultrasonography (CEUS) LI-RADS system in the differential diagnosis of hepatocellular carcinoma (HCC). Information sources: A comprehensive and thorough search of literature was carried out through internationally acknowledged medical literature resources database, including PubMed/MEDLINE, EMBASE, Ovid, and Web of Science along with regional databases with key research words of (“hepatocellular carcinoma” OR “liver cancer” OR “liver tumor” OR “liver nodule” O
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Xiaole, Peng Wang, Yunquan Luo, et al. Therapeutic Efficacy Evaluation and Underlying Mechanisms Prediction of Jianpi Liqi Decoction for Hepatocellular Carcinoma. Science Repository, 2021. http://dx.doi.org/10.31487/j.jso.2021.02.04.sup.

Full text
Abstract:
Objective: The aim of this study was to assess the therapeutic effects of Jianpi Liqi decoction (JPLQD) in hepatocellular carcinoma (HCC) and explore its underlying mechanisms. Methods: The characteristics and outcomes of HCC patients with intermediate stage B who underwent sequential conventional transcatheter arterial chemoembolization (cTACE) and radiofrequency ablation (RFA) only or in conjunction with JPLQD were analysed retrospectively. The plasma proteins were screened using label-free quantitative proteomics analysis. The effective mechanisms of JPLQD were predicted through network pha
APA, Harvard, Vancouver, ISO, and other styles
4

Tangkijvanith, Pisit. Prevalence and Clinical Significance of Hepatitis B Viral Genotypes and Mutations. Faculty of Medicine, Chulalongkorn University, 2006. https://doi.org/10.58837/chula.res.2006.24.

Full text
Abstract:
Hepatitis B virus (HBV) infection is a major public health problem, with more than 400 million HBV carriers estimated worldwide. Chronic HBV infection is associated with a diverse clinical spectrum of liver damage ranging from asymptomatic carrier status, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). There have been increasing lines of evidence to indicate influences of HBV genotypes and mutations on the outcome of liver disease, particularly the development of HCC. The project is aimed to study the prevalence and clinical significance of genotypes and mutations in Precore/
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hepatocellular Carcinoma HSC' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography